KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Current Investments (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Cash & Current Investments data on record, last reported at $215.8 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 31175.22% year-over-year to $215.8 million; the TTM value through Sep 2025 reached $298.7 million, up 282.98%, while the annual FY2025 figure was $215.8 million, 31175.22% up from the prior year.
  • Cash & Current Investments reached $215.8 million in Q4 2025 per PACB's latest filing, down from $298.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $1.0 billion in Q4 2021 and bottomed at $690000.0 in Q4 2024.
  • Average Cash & Current Investments over 5 years is $411.2 million, with a median of $320.1 million recorded in 2022.
  • Peak YoY movement for Cash & Current Investments: tumbled 99.89% in 2024, then soared 31175.22% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $1.0 billion in 2021, then crashed by 68.84% to $325.4 million in 2022, then soared by 94.05% to $631.4 million in 2023, then crashed by 99.89% to $690000.0 in 2024, then skyrocketed by 31175.22% to $215.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $215.8 million in Q4 2025, $298.7 million in Q3 2025, and $314.7 million in Q2 2025.